Dextromethorphan O-demethylase activity in rat brain microsomes

[1]  G. Tucker,et al.  The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). , 1994, Biochemical pharmacology.

[2]  M. Ames,et al.  Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. , 1977, Biochemical and biophysical research communications.

[3]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[4]  R. Foltz,et al.  Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. , 1991, Chemical research in toxicology.

[5]  P. M. Daniel,et al.  Comparison of the Vascular Permeability of the Brain and the Spinal Cord to Mannitol and Inulin in Rats , 1985, Journal of neurochemistry.

[6]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[7]  U. Meyer,et al.  MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. , 1987, Biochemical and biophysical research communications.

[8]  M. Ingelman-Sundberg,et al.  Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system , 1990, Neuroscience.

[9]  C. Alm,et al.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. , 1989, British journal of clinical pharmacology.

[10]  T. F. Murray,et al.  High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. , 1992, Molecular pharmacology.

[11]  J. Idle,et al.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. , 1982, British medical journal.

[12]  M. Ingelman-Sundberg,et al.  Different regiospecificity in the hydroxylation of the antidepressant desmethylimipramine between rat brain and liver. , 1992, Pharmacology & toxicology.

[13]  G. Siest,et al.  Distribution of cytochrome P450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels. , 1990, Biochemical pharmacology.

[14]  G. Siest,et al.  Subcellular distribution of cytochrome P-450 in the brain , 1986, Brain Research.

[15]  L. Bertilsson,et al.  Relationship between personality and debrisoquine hydroxylation capacity , 1993, Acta psychiatrica Scandinavica.

[16]  H. W. Elliott,et al.  N- AND O-DEMETHYLATION OF SOME NARCOTIC ANALGESICS BY BRAIN SLICES FROM MALE AND FEMALE LONG-EVANS RATS. , 1963, Biochemical pharmacology.

[17]  Peter Bjerring,et al.  Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine , 1990, Clinical pharmacology and therapeutics.

[18]  W. Kalow.  Pharmacogenetic variability in brain and muscle. , 1994, The Journal of pharmacy and pharmacology.

[19]  G. Siest,et al.  Drug metabolizing enzymes in the brain and cerebral microvessels , 1991, Brain Research Reviews.

[20]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[21]  R. Branch,et al.  Genetically determined polymorphisms in drug oxidation , 1986, Hepatology.

[22]  G. Siest,et al.  Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. , 1993, Biochemical pharmacology.

[23]  J. Gustafsson,et al.  Cytochrome P450s of the 4A Subfamily in the Brain , 1994, Journal of neurochemistry.

[24]  R. Tyndale,et al.  Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. , 1991, Molecular pharmacology.